Oral, once-daily Orladeyo (berotralstat) from BioCryst Pharmaceuticals, Inc. was approved by the European Medicines Agency (EMA) on 30 April 2021 for the prevention of recurrent HAE attacks in patients 12 years and older – and now the product is available for patients with a prescription in Germany.
“We have an experienced team in place in Germany that is excited and honored to bring the first oral, once daily therapy to HAE patients in Europe,” says Charlie Gayer, Chief Commercial Officer of BioCryst. “Patients and physicians across Europe have told us about the significant need for a targeted oral therapy for HAE, and Germany is the first of many upcoming European launches for Orladeyo.”
(Source: BioCryst)
